Nitrogen-containing bisphosphonate incadronate augments the inhibitory effect of farnesyl transferase inhibitor tipifarnib on the growth of fresh and cloned myeloma cells in vitro

References

• Rowinski E K, Windle J J, von Hoff D D. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J Clin Oncol 1999; 17: 3631–3652
   PubMed Web of Science ®Google Scholar
• Beaupre D M, Kurzrock R. Ras and leukemia: from basic mechanisms to gene-detected therapy. J Clin Oncol 1999; 17: 1071–1079
   PubMed Web of Science ®Google Scholar
• Reuter C WM, Morgan M A, Bergmann L. Targeting the ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?. Blood 2000; 96: 1655–1669
   PubMed Web of Science ®Google Scholar
• Corradini P, Ladetto M, Voena C, Palumbo A, Inghirami G, Knowles D M, et al. Mutational activation of N-and K-ras oncogenes in plasma cell dyscrasias. Blood 1993; 81: 2708–2713
   PubMed Web of Science ®Google Scholar
• Paquette R L, Berenson J, Lichtenstein A, McCormic F, Koeffler H P. Oncogenes in multiple myeloma: point mutation of N-ras. Oncogene 1990; 5: 1659–1663
   PubMed Web of Science ®Google Scholar
• Liu P, Leong T, Quam L, Billadeau D, Kay N E, Greipp P, et al. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group phase III trial. Blood 1996; 88: 2699–2706
   PubMed Web of Science ®Google Scholar
• Kalakonda N, Rothwell D G, Scarffe J H, Norton J D. Detection of N-ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma. Blood 2001; 98: 1555–1560
   PubMed Web of Science ®Google Scholar
• Karp J E. Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies. Semin Hematol 2001; 38(suppl 7)16–23
   PubMed Web of Science ®Google Scholar
• End D W, Smets G, Todd A V, Applegate T L, Fuery C J, Angibaud P, et al. Characterization of the antitumor effect of the selective farnesyl transferase inhibitor R115777 in vivo and in vitro. Cancer Res 2001; 61: 131–137
   PubMed Web of Science ®Google Scholar
• Gouill S L, Pellat-Deceunynck C, Harroseau J -L, Rapp M -J, Robillard N, Bataille R, et al. Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells. Leukemia 2002; 16: 1664–1667
   PubMed Web of Science ®Google Scholar
• Ochiai N, Uchida R, Fuchida S, Okano A, Okamoto M, Ashihara E, et al. Effect of farnesyl transferase inhibitor R115777 on the growth of fresh and cloned myeloma cells in vitro. Blood 2003; 102: 3349–3353
   PubMed Web of Science ®Google Scholar
• Zujewski J, Horak I D, Bol C J, Woestenborghs R, Bowden C, End D W, et al. Phase 1 and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 2000; 18: 927–941
   PubMed Web of Science ®Google Scholar
• Karp J E, Lancet J E, Kaufmann S H, End D W, Wright J J, Bol K, et al. Clinical and biologic activity of the farnesyl transferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 2001; 97: 3361–3369
   PubMed Web of Science ®Google Scholar
• Alsina M, Fonseca R, Wilson E F, Belle A N, Gerbino E, Price-Troska T, et al. The Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 2004; 103: 3271–3277
   PubMed Web of Science ®Google Scholar
• Cortes J, Albitar M, Thomas D, Giles F, Kurzrock R, Thibault A, et al. Efficacy of the farnesyl transferase inhibitor, Zarnestra™ (R115777), in chronic myeloid leukemia and other hematologic malignancies. Blood 2003; 101: 1692–1697
   PubMed Web of Science ®Google Scholar
• Santucci R, Mackley P A, Sebti S, Alsina M. Farnesyltransferase inhibitors and their role in the treatment of multiple myeloma. Cancer Control 2003; 10: 384–387
   PubMedGoogle Scholar
• Kohl N E, Wilson F R, Mosser S D, Giuliani E, deSolms S J, Conner M W, et al. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci USA 1994; 91: 9141–9145
   PubMed Web of Science ®Google Scholar
• James G, Goldstein J L, Brown M S. Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells. Proc Natl Acad Sci USA 1996; 93: 4454–4458
   PubMed Web of Science ®Google Scholar
• Rowell C A, Kowalczyk J J, Lewis M D, Garcia A M. Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J Biol Chem 1997; 272: 14093–14097
   PubMed Web of Science ®Google Scholar
• Whyte D B, Kirschmeimer P, Hockenberry T N, Nunez-Oliva I, James L, Catino J J, et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 1997; 272: 14459–14464
   PubMed Web of Science ®Google Scholar
• Feldkamp M M, Lau N, Roncari L, Guha A. Isotype-specific Ras GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status. Cancer Res 2001; 61: 4425–4431
   PubMed Web of Science ®Google Scholar
• Beaupre D M, Cepero E, Obeng E A, Boise L H, Lichtenheld M G. R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways. Mol Cancer Ther 2004; 3: 179–186
   PubMed Web of Science ®Google Scholar
• Berenson J R, Lightenstein A, Porter L, Domopoulos M A, Bordoni R, George S, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996; 334: 488–493
   PubMed Web of Science ®Google Scholar
• Shipman C M, Croucher P I, Russell R GG, Helfrich M H, Rogers M J. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 1998; 61: 5294–5297
   Google Scholar
• Luckman S P, Hughes D E, Coxon F P, Russell R GG, Rogers M J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998; 13: 581–589
   PubMed Web of Science ®Google Scholar
• Takahashi R, Shimazaki C, Inaba T, Okano A, Hatsuse M, Okamoto A, et al. A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells. Leukemia Res 2001; 25: 77–83
   PubMed Web of Science ®Google Scholar
• Goldstein J L, Brown M S. Regulation of the mevalonate pathway. Nature 1990; 343: 425–430
   PubMed Web of Science ®Google Scholar
• Jego G, Robillard N, Puthier D, Amiot M, Accard F, Pineau D, et al. Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells. Blood 1999; 94: 701–712
   PubMed Web of Science ®Google Scholar
• Herault O, Colombat P, Domenech J, Degenne M, Bremond J -L, Sensebe L, et al. A rapid single-laser flow cytometric method for discrimination of early apoptotic cells in a heterogenous cell population. Br J Hematol 1999; 104: 530–537
   PubMed Web of Science ®Google Scholar
• Ahmed S A, Gogal R M, Jr, Walsh J E. A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]-thymidine incorporation assay. J Immunol Methods 1994; 170: 211–224
   PubMed Web of Science ®Google Scholar
• Peters D G, Hoover R R, Gerlach M J, Koh E Y, Zhang H, Choe K, et al. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood 2001; 97: 1404–1412
   PubMed Web of Science ®Google Scholar
• Sepp-Lorenzino L, Ma Z, Rands E, Kohl N E, Gibbs J B, Oliff A, et al. A peptidomimetic inhibitor of farnesyl protein transferase blocks the anchorange-dependent and -independent growth of human tumor cell lines. Cancer Res 1995; 15: 5302–5309
   Google Scholar
• Mazet J L, Padieu M, Osman H, Maume G, Mailliet P, Dereu N, et al. Combination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-289 disrupts MAP kinase activatiomn and G1-S transition in Ki-Ras-overexpressing transformed adenocortical cells. FEBS Letters 1999; 460: 235–240
   PubMed Web of Science ®Google Scholar
• Hu L, Shi Y, Hsu J -H, Gera J, Van Ness B, Lichtenstein A. Downstream effectors of oncogenic Ras in multiple myeloma cells. Blood 2003; 101: 3126–3135
   PubMed Web of Science ®Google Scholar
• Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002; 99: 1745–1757
   PubMed Web of Science ®Google Scholar